Begin main content

Pegfilgrastim

Last Updated: May 8, 2018
Result type: Reports
Project Number: SE0555-000
Product Line: Common Drug Review

Generic Name: Pegfilgrastim

Brand Name: Lapelga

Manufacturer: Apobiologix

Indications: Febrile neutropenia

Manufacturer Requested Reimbursement Criteria1: As the preferred pegfilgrastim product to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

Submission Type: New

Project Status: Complete

Biosimilar: Yes

Fee Schedule: Schedule D

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedDecember 14, 2017
Patient group input closedFebruary 09, 2018
Clarification:

- No patient input submission received

Submission receivedFebruary 23, 2018
Submission accepted for reviewMarch 02, 2018
Review initiatedMarch 05, 2018
Draft CDR review report(s) sent to applicantApril 19, 2018
Comments from applicant on draft CDR review report(s) receivedApril 24, 2018
Final CDR review report(s) sent to applicantApril 30, 2018
Final CDR review report(s) postedMay 08, 2018

Tags

blood, cancer, sweet syndrome, febrile neutropenia; Non-myeloid malignancies; Non-myeloid malignancy; lapelga; pegfilgrastim; neulasta; biosimilar